In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
News|Articles|April 9, 2026
Q1 2026 Recap: Endocrinology News and Updates
Author(s)Ryan Livingston
Fact checked by: Chelsie Derman
Catch up on FDA decisions, new GLP-1 agonists, and more.
Advertisement
Advertisement
Endocrinology is off to a stellar start in 2026, with a first quarter packed full of major FDA approvals and trial results. Orforglipron, now approved for
Related to this article
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.
Advertisement
Advertisement